• Able to understand the informed consent form, voluntarily participate in and sign the informed consent form;

• Gender is not limited;

• Age: ≥18 years old and ≤75 years old (stage Ia); ≥18 years old (stage Ib);

• Locally advanced or metastatic breast cancer and other solid tumors;

• Must have at least one measurable lesion that meets the RECIST v1.1 definition;

• Have archived primary or recurrent tumor tissue specimens that can be submitted for central review;

• ECOG ≤1;

• The expected survival time as judged by the investigators was ≥3 months;

• Bone marrow function, renal function and liver function should meet the requirements;

⁃ Coagulation function: fibrinogen ≥1.5g/L; Activated partial thromboplastin time (APTT) ≤1.5×ULN; Prothrombin time (PT) ≤1.5×ULN;

⁃ Fertile female subjects or male subjects with fertile partners must use highly effective contraception from 7 days before the first dose until 12 weeks after the last dose. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose;

⁃ Subjects were able and willing to comply with protocol-specified visits, treatment plans, laboratory tests, and other study-related procedures.